Date:4/11/2011

tions and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

Kim Baker/Gene CarozzaPAREXEL International

PAN CommunicationsTel: +781-434-4409

Tel: + 978-474-1900Email: Jennifer.Baird@PAREXEL.com

Email: PAREXEL@pancomm.com
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region